Skip to content

Discontinued — last reported Q4 '24

Free cash flow at other companies

Bausch Health Companies logo
Bausch Health CompaniesBHC
$121M+26.0%
Cumberland Pharmaceuticals logo
Cumberland PharmaceuticalsCPIX
$387.03K-89.9%
PTH
Pelthos Therapeutics Inc.PTHS
-$13.32M-2,008%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$2.24M+107%
HRO
HarrowHROW
-$9.19M-147%
Catalyst Pharmaceutical logo
Catalyst PharmaceuticalCPRX
$59.56M-0.8%

Other financials

Income statement

See full
Revenue$16.0M+21.5%
Gross profit$9.7M+16.7%
Operating income-$1.5M+55.1%
Net income-$2.2M+45.2%
EPS (diluted)-$0.08+55.6%

Balance sheet

See full
Cash & equivalents$27.2M+29.2%
Total debt$25.5M+1.2%
Total equity$30.8M+43.1%
Total assets$91.5M+7.7%

Cash flow

See full
Operating cash flow$2.9M+203%
CapEx$3.8M

Valuation

See full
Market cap$194.94M+20.9%
Enterprise value$193.19M+16.2%
P/S+0.2×

Profitability

See full
Gross margin65.4%-1.0pp
Operating margin-9.8%
Net margin-14.8%
FCF margin-43%

Returns & leverage

See full
Return on equity-36.6%
Debt / equity0.8×-0.3×
Current ratio1.7×+0.4×

Where this comes from

Calculated from Journey Medical Corporation’s reported figures.

Plus components not separately reported this period.

The official record: Journey Medical Corporation’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →

Ask your AI about Journey Medical Corporation's free cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Journey Medical Corporation's free cash flow?
Journey Medical Corporation (DERM) reported free cash flow of -$6.03M in Q4 2024.
What is the long-term trend for Journey Medical Corporation's free cash flow?
Over 2 years (2021 to 2024), Journey Medical Corporation's free cash flow has grown at a 232.6% compound annual growth rate (CAGR), from -$2.18M to -$24.13M.
What does free cash flow mean?
Free cash flow represents the cash generated by a company after accounting for cash outflows to support operations and maintain or expand its capital asset base. It serves as a critical indicator of a company's ability to fund organic growth, pay down debt, or return capital to shareholders without relying on external financing.